Inventors:
Motoo Nagane - La Jolla CA
Webster Cavenee - La Jolla CA
Su Huang - La Jolla CA
Assignee:
Ludwig Institute for Cancer Research - New York NY
International Classification:
A61K 3800
Abstract:
The invention relates to compositions which include both a DR5 binding ligand, such as TRAIL, and a DNA damaging agent. In combination, these two materials have unexpected efficacy in treating conditions involving rapid cellular turnover, such as cancer, where an increase in apoptosis is desired. The compositions are particularly effective in treating neoplasias and diseases involving proliferative lesions, such as glioma.